If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
182
results.
Updated on
15/11/2026 [07:06:00]
Results 50 to 75 of 182
Absstract of: WO2026221010A1
The present disclosure provides a method for identifying a treatment that promotes differentiation of a first cell into a second cell. The present disclosure also provides pancreatic beta cells or cells that are capable of differentiating into pancreatic beta cells. In the present disclosure, the pancreatic beta cells or cells that are capable of differentiating into pancreatic beta cells have a deletion of a specific gene, whereby the same preferably exhibit a high capability of differentiating into pancreatic beta cells, or exhibit a capability of differentiating into pancreatic beta cells exhibiting a glucose-dependent C-peptide secretion ability.
Absstract of: AU2026242160A1
The present disclosure relates to compositions and methods for treating liver cancers, especially hepatocellular carcinoma, using antisense (AS) nucleic acids directed against Insulin- like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of liver cancer. ep e p
Absstract of: US20260325016A1
0000 Provided are a blood glucose management system using a continuous glucose monitor and a method therefor. The blood glucose management system may include a data collector configured to collect blood glucose data measured through a continuous glucose monitor worn by a patient; a data analyzer configured to analyze the collected blood glucose data to calculate values of a plurality of blood glucose variables representing a blood glucose state of the patient; and a data provider configured to provide the values of the blood glucose variables through a monitoring board. By using the system, the blood glucose states of patients can be thoroughly monitored and managed.
Absstract of: US20260325752A1
0000 Techniques disclosed herein relate to infusion devices and related meal bolus adjustment methods. In some embodiments, the techniques may involve determining an initial bolus amount to compensate for food consumption. The techniques may further involve predicting an initial value for a physiological condition based at least in part on the initial bolus amount and one or more insulin deliveries. The techniques may further involve identifying an adjusted bolus amount based on the predicted value. The techniques may further involve causing delivery of the adjusted bolus amount.
Absstract of: US20260327567A1
0000 Provided are a cell culture product and the use thereof. The cell culture product comprises a hepatic progenitor cell proliferation medium, containing a DMEM/F12 medium, insulin, transferrin, sodium selenite, nicotinamide, 2-phosphate-L-ascorbic acid, a human recombinant albumin, an epidermal cell growth factor, a glycogen synthase kinase 3 inhibitor, a transforming growth factor β receptor inhibitor, lysophosphatidic acid, and sphingosine phosphate.
Absstract of: AU2025249757A1
A variability metric of glucose level values of a user is calculated for each candidate sleeping time frame in a data set of glucose level values of the user obtained over time for a specified period for each day of multiple days. Each of the candidate sleeping time frames may represent a duration in which the user may have been sleeping. Execution of the programming instructions further may cause the processor to determine a mean or median of the variability metric of the glucose level values in the data set for each candidate sleeping time frame across the days in the specified period, designate a selected one of the candidate sleeping time frames that has the lowest mean or median variability metric as the sleeping time frame, and configure the pump to deliver a sleeping basal rate of the medicament for the designated sleeping time frame.
Absstract of: US20260325852A1
The present disclosure relates to a device for applying electrical stimulation to biological tissues. Specifically, the present disclosure is related to a device for applying anodal/cathodal biphasic electrical stimulation to beta cells of the pancreas. Through application of biphasic stimulation to beta cells of the pancreas, insulin secretion can be increased in an effort to overcome deficiencies associated with diabetic patients.
Absstract of: AU2025255066A1
The present invention relates to a cytidine diphosphocholine glycoside represented by general formula (1), a salt thereof, an N-oxide thereof, a solvate thereof, or the like. (In formula (1), R is a sugar residue.)
Absstract of: AU2025254093A1
Methods, systems, and devices for evaluating a user's metabolic balance are described. A system may include a wearable device and a glucose monitoring device. The system may acquire physiological data from the wearable device, and blood glucose data from the glucose monitoring device. The system may be configured to determine physiological characteristics of the user based on the physiological data, such characteristics associated with a sleep quality of the user, a stress level of the user, an activity level of the user, a recovery of the user, or any combination thereof. Similarly, the system may identify metabolic characteristics of the user, such as changes in the user's blood glucose data. By overlaying and comparing the physiological data and the blood glucose data, the system may be able to evaluate how the user's physiological characteristics affect or impact the user's metabolic characteristics, or vice versa.
Absstract of: US20260325585A1
Disclosed herein are methods, systems, and compositions for enhancing the effectiveness of β-cell (Beta-cell)-based therapies. Also disclosed herein are methods, systems, and compositions related to identifying, sorting and separating heterogeneous populations of stem cell-derived pancreatic β-cells (sBCs) into more useful and functionally homogeneous cell populations. In many embodiments, the most mature and functional of the sBCs are identified and live-sorted using the cell surface protein Ectonucleoside Triphosphate Diphosphohydrolase-3 (ENTP3), which is also referred to as CD39L3. The presently disclosed methods, systems, and compositions are useful for cell therapies, for example replacement therapy. In many embodiments the disclosed systems, methods, and compositions are useful in treatments for diabetes. In some embodiments, the disclosed methods, systems, and compositions may be useful in treating, preventing, and/or curing diabetes, for example type-1 diabetes.
Absstract of: AU2026242121A1
Recommendations based on continuous glucose monitoring (CGM) are described. Given the number of people that wear CGM systems and because CGM systems produce measurements continuously, a platform that provides a CGM system may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process. In implementations, a CGM platform includes a data analytics platform that obtains glucose measurements provided by a CGM system and also obtains additional data associated with a user. The data analytics platform processes these measurements and the additional data to predict a health indicator by using models. This prediction serves as a basis for generating a recommendation, such as a message recommending the user take action or adopt a behavior to mitigate a predicted negative health condition. ep e p
Absstract of: US20260325017A1
0000 Methods, devices and system for determining fasting glucose level information and post-prandial glucose level information for diagnosing pre-diabetic and diabetic conditions based on monitored glucose measurements are provided.
Absstract of: US20260325582A1
0000 The purpose of the present invention is to provide a novel therapeutic agent for renal disease. The present invention is a therapeutic agent for renal disease containing a mesenchymal stem cell culture supernatant. The mesenchymal stem cell culture supernatant is preferably a culture supernatant obtained from the cultivation of mesenchymal stem cells derived from adipose tissue, umbilical tissue, or bone marrow tissue. In addition, the mesenchymal stem cell culture supernatant is preferably obtained from the cultivation of mesenchymal stem cells in a culture medium containing at least one substance selected from the group consisting of EGF, bFGF, albumin, transferrin, and insulin.
Absstract of: WO2025128082A1
A system and method for wireless transmission of glucose data. According to an embodiment of the present disclosure, there is provided a system, including: a glucose sensor; a beacon transmitter; and a processing circuit connected to the glucose sensor and the beacon transmitter, the processing circuit being configured to transmit a data packet, the data packet including measurement data including a measurement value, the measurement value being based on a glucose measurement.
Absstract of: AU2015325028A1
Recombinant human alpha glucosidase (rhGAA) composition derived from CHO cells that contains a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs, along with low amount of non-phosphorylated high mannose glycans, and low amount of terminal galactose on complex oligosaccharides. Compositions containing the rhGAA, and methods of use are described.
Absstract of: US20260321378A1
0000 Provided are systems and methods using which users may learn and become familiar with the effects of various aspects of their lifestyle on their health, e.g., users may learn about how food and/or exercise affects their glucose level and other physiological parameters, as well as overall health. In some cases the user selects a program to try; in other cases, a computing environment embodying the system suggests programs to try, including on the basis of pattern recognition, i.e., by the computing environment determining how a user could improve a detected pattern in some way. In this way, users such as type II diabetics or even users who are only prediabetic or non-diabetic may learn healthy habits to benefit their health.
Absstract of: AU2026238070A1
11201607_1 (GHMatters) P110945.AU Disclosed is an expression regulatory system for cell-specific transcription (expression) of a protein of interest, for example a cell cycle inducer that reactivates proliferation in adult or neonatal cardiomyocytes or insulin-producing beta cells. The expression regulatory system comprises a first nucleic acid that encodes a microRNA recognition element that specifically binds a target cell miR, and a translation suppressor protein; and a second nucleic acid that comprises a suppressor protein interaction motif that binds the translation suppressor protein, and a gene that encodes a protein of interest. When a cell of interest is co-transfected with the first and second nucleic acids of the system, the protein of interest expressed in a cell-specific fashion. ep e p
Absstract of: US20260314958A1
0000 The present invention proposes a method of measuring the real-time level and degree of management of blood sugar based on an electrocardiogram. The method includes: obtaining an electrocardiogram signal measured for a user; estimating the user's blood sugar level by analyzing the electrocardiogram signal using a pre-trained first artificial intelligence, and determining whether the user has hyperglycemia or hypoglycemia by analyzing the electrocardiogram signal using an artificial intelligence; and determining whether the user needs guidance on blood sugar or diabetes based on the estimated blood sugar level and the result of the determination of whether the user has hyperglycemia or hypoglycemia. Through this, a user may check the user's immediate blood sugar level and how well the blood sugar is managed simply by measuring the electrocardiogram 10, and as a result, hyperglycemia and diabetes may be detected early or a complication attributable to hyperglycemia or diabetes may be prevented.
Absstract of: US20260315009A1
An autoregressive framework for synthetic data generation using an autoregressive generative model as an alternative to Generative Adversarial Networks (GAN). The autoregressive framework is applied to continuous glucose monitor data uses small real datasets to generate synthetic glycemic responses. The framework performs better than other systems because it works well with data constrained environments and can also evaluate contextual values in addition to past values.
Absstract of: WO2026214700A1
Provided in the present invention are a GLP-1/GLP-2 bispecific polypeptide and a fusion protein in which said polypeptide is fused to human IgG4-Fc. The GLP-1/GLP-2 bispecific polypeptide provided by the present invention can simultaneously activate GLP-1 and GLP-2 receptors, has a blood sugar control capability close to that of semaglutide, has a significant trophic effect on the small-intestine equivalent to that of teduglutide, and can markedly improve pathological features in mice with ulcerative colitis (UC).
Absstract of: WO2026217569A1
Methods and compositions for treating Alzheimer's disease and related neurodegenerative conditions using intranasal nose-to-brain delivery of ST266, an amnion-derived cell secretome are described. ST266 is a multi-component, acellular biologic composition produced from amnion-derived multipotent progenitor (AMP) cells under cGMP conditions and comprising a plurality of anti-inflammatory, neuroprotective, anti-apoptotic, and regenerative cytokines and growth factors. When administered intranasally, ST266 bypasses the blood-brain barrier and simultaneously targets multiple pathological mechanisms underlying Alzheimer's disease, including neuroinflammation, insulin dysregulation, oxidative stress, neuronal damage, and synaptic dysfunction. The invention encompasses pharmaceutical compositions formulated for intranasal nose-to-brain delivery, methods of treating Alzheimer's disease by administering such compositions, and methods of reducing neuroinflammation and improving insulin regulation in the central nervous system. The non-invasive nature of intranasal delivery offers significant advantages in patient compliance and minimization of systemic side effects.
Absstract of: US20260314961A1
A blood glucose level measurement device includes a sensor portion that measures a blood glucose level of a user, a communication portion that transmits data representing the blood glucose level measured by the sensor portion to the outside, a flexible, sheet-shaped battery that supplies power to the sensor portion and the communication portion, a flexible, plate-shaped circuit portion that controls the operation of the communication portion, and an attachment portion configured to be attached to the body of the user. The battery has a peak current of 20 mA or more.
Absstract of: US20260315755A1
Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
Absstract of: AU2026242095A1
Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes 5 and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein. ep e p
Nº publicación: US20260315694A1 15/10/2026
Applicant:
INSULET CORP [US]
INSULET CORPORATION
Absstract of: US20260315694A1
0000 Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.
BOPI
Electronic site
